• Mashup Score: 0

    February 25, 2022 – Teleflex Incorporated, a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for its specialty catheters and coronary guidewires for use in crossing chronic total occlusion percutaneous coronary interventions (CTO PCI). CTOs are longstanding complete blockages in coronary arteries…

    Tweet Tweets with this article
    • @DAICeditor @TeleflexCardiol Results of CTO-PCI IDE study demonstrate procedural success with #Teleflex specialty #catheters and #coronary #guidewires in patients undergoing chronic total #occlusion #percutaneous #coronary interventions: https://t.co/YbIrXtjhdv

  • Mashup Score: 0

    Percutaneous coronary intervention (PCI) rates dropped by almost 10% between 2010 and 2017, according to a new analysis published in JAMA Cardiology. A 34% decline in elective PCI rates between 2010 and 2013 was the main catalyst for the overall decrease. “These trends differ from prior studies that showed a greater decline (approximately 23%) in PCIs over the same period, which is most likely…

    Tweet Tweets with this article
    • Decline in elective PCI associated with overall decline in rates #Percutaneous coronary intervention (PCI) https://t.co/P7vPjLSv1O